为您找到相关结果约500个

你是不是要搜索 期刊METex14跳跃变异 点击跳转

Tepotinib in Asian patients with advanced NSCLC with MET exon 14 (METex14) skipping

Tepotinib in Asian patients with advanced NSCLC with MET exon 14 (METex14) skipping.

Tepotinib in Asian patients (pts) with advanced NSCLC with MET exon 14 (METex14) skipping

Tepotinib safety in MET exon 14 (METex14) skipping NSCLC: Updated results from the VISION trial

Tepotinib Safety in MET Exon 14 (METex14) Skipping NSCLC: Updated Results from the VISION Trial

Tepotinib outcomes according to prior therapies in patients with MET exon 14 (METex14) skipping NSCLC

PREVALENCE OF MET EXON 14 (METEX14) SKIPPING IN PATIENTS WITH ADVANCED NSCLC: A SYSTEMATIC LITERATURE

Clinical characteristics of patients with advanced NSCLC and METexon 14 (METex14) skipping: A systematic

Treatment sequencing in the VISION study of tepotinib in patients with METexon 14 (METex14) skipping

ABN401 in patients with NSCLC with MET exon 14 (METex14) skipping: Result from the pilot expansion study

Intracranial Activity of Tepotinib in Patients (pts) With MET exon 14 (METex14) Skipping NSCLC Enrolled

Efficacy and intracranial activity of tepotinib in Japanese patients with MET exon 14 skipping (METex14

Updated molecular analysis of MET exon 14 skipping mutations (METex14) in non-small cell lung cancer

Characterization of 1,387 NSCLCs with MET exon 14 (METex14) skipping alterations (SA) and potential acquired

Tepotinib in patients with MET exon 14 (METex14) skipping advanced NSCLC: Updated efficacy results from

为您找到相关结果约500个

共500条页码: 1/34页15条/页